SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
André J
AJ
Scheen
D001559:Benzhydryl Compounds; D002318:Cardiovascular Diseases; D003924:Diabetes Mellitus, Type 2; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D005960:Glucosides; D006801:Humans
D001559:Benzhydryl Compounds; D005960:Glucosides; C570240:empagliflozin
CLINICAL PHARMACOLOGY